semaglutide arthritis ameliorates osteoarthritis progression through a weight loss-independent metabolic restoration mechanism A new drug can actually

The idea behind this is that the two proteins target different steps of the regeneration process, one being migration and mobilization of the cytoskeleton, and the other one being vascularization and cytoprotection

In Phase 2 trials published in the *New England Journal of Medicine* (2023), participants lost an average of 17.5% of body weight at the highest dose over 24 weeks outperforming tirzepatide and semaglutide in head-to-head data comparisons

PMID 10652368

Severe gastrointestinal issues: Individuals with a history of severe gastrointestinal problems, such as gastroparesis or pancreatitis, should steer clear of this medication, as semaglutide can exacerbate these conditions